Studies platelet changes in patients on ECMO heart and lung support
Observes how platelet populations change in adults with heart or lung failure on ECMO.
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- Strasbourg, FranceSee the site
- Trial code
- Registry title
- Study of Platelet Population Changes Under Circulatory Support With ECMO
- Status
- Recruiting
- People taking part
- 75 people, planned
- Started
- 11 Mar 2025
- Expected to end
- 11 Mar 2027
- Type of study
- Observational
- Record updated
- 12 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in an intensive care unit at Strasbourg University Hospital who received ECMO (heart-lung support machine) within the last 24 hours.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Heart failure or respiratory failure treated with veno-arterial or veno-venous ECMO started within the previous 24 hours
- Earlier treatment
- ECMO implanted within the previous 24 hours
Main reasons for not taking part
- Person who has said they do not want to take part
- Person under legal protection
- Person under guardianship or curatorship
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital
- Implanted with veno-arterial or veno-venous ECMO within the previous 24 hours
Who cannot take part
- Subject who has expressed their opposition to participating in the study
- Subject under legal protection
- Subject under guardianship or curatorship
Where in France
- Service d'anesthésie-réanimation - CHU de Strasbourg - FranceStrasbourg, FranceContact: Charles TACQUARD, MD, PhDTaking people
About the trial
What the trial wants to find out
Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). These phenotypes have a significant impact on the hemostatic capacity of blood platelets, and a proportional change in these populations during ECMO treatment could, at least in part, contribute to the observed complications.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study of Platelet Population Changes Under Circulatory Support With ECMO
- Plain-language title
- Studies platelet changes in patients on ECMO heart and lung supportGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 January 2026